Scandion Oncology A/S

Scandion Oncology is a clinical phase II biotech company with its focus on novel and innovative drugs and biomarkers to combat anti-cancer drug resistance. Scandion Oncology has three drug candidates in its pipeline. The most advanced drug candidate is SCO-101, which is ready for clinical phase II testing. The current global market for SCO-101 in metastatic breast- and colorectal cancer may exceed EUR 4 billion in annual sales. There are no drugs on the market that can reverse/suspend anti-cancer drug resistance.

Läs mer på företagets hemsida

Detaljinfo & filer

20/6 - 09/7 2019